Chemokine (C-C Motif) Ligand 8 and Tubulo-Interstitial Injury in Chronic Kidney Disease

Kidney fibrosis has been accepted to be a common pathological outcome of chronic kidney disease (CKD). We aimed to examine serum levels and tissue expression of chemokine (C-C motif) ligand 8 (CCL8) in patients with CKD and to investigate their association with kidney fibrosis in CKD model. Serum levels and tissue expression of CCL8 significantly increased with advancing CKD stage, proteinuria level, and pathologic deterioration. In Western blot analysis of primary cultured human tubular epithelial cells after induction of fibrosis with rTGF-beta, CCL8 was upregulated by rTGF-beta treatment and the simultaneous treatment with anti-CCL8 mAb mitigated the rTGF-beta-induced an increase in fibronectin and a decrease E-cadherin and BCL-2 protein levels. The antiapoptotic effect of the anti-CCL8 mAb was also demonstrated by Annexin V/propidium iodide staining assay. In qRT-PCR analysis, mRNA expression levels of the markers for fibrosis and apoptosis showed similar expression patterns to those observed by western blotting. The immunohistochemical analysis revealed CCL8 and fibrosis- and apoptosis-related markers significantly increased in the unilateral ureteral obstruction model, which agrees with our in vitro findings. In conclusion, CCL8 pathway is associated with increased risk of kidney fibrosis and that CCL8 blockade can ameliorate kidney fibrosis and apoptosis.

Automated summary

This study found that chemokine (C-C motif) ligand 8 (CCL8) levels increased with the progression of chronic kidney disease (CKD). In vitro experiments showed that CCL8 was upregulated by fibrosis-inducing factor rTGF-beta, and blocking CCL8 could mitigate fibrosis and apoptosis. These findings suggest that the CCL8 pathway is associated with kidney fibrosis and blocking CCL8 could be a potential therapeutic strategy.